ThromboGenics NV (THR)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:ThromboGenics NV (THR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012300
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ベルギー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ThromboGenics NV (ThromboGenics) is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The company’s ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT). ThromboGenics’s product pipeline includes THR-409 (ocriplasmin) under evaluation for inducing total posterior vitreous detachment in patients with non-proliferative diabetic retinopathy; THR-317 for diabetic macular edema; THR-687 and THR-149 for diabetic retinopathy. ThromboGenics spun off its oncology research in a joint venture with VIB (Flanders Institute for Biotechnology) into Oncurious NV, which focuses on the treatment of pediatric brain tumors. It has a presence in Belgium, Ireland and the US. ThromboGenics is headquartered in Leuven, Flemish Brabant, Belgium.

ThromboGenics NV (THR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ThromboGenics NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
ThromboGenics NV, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
ThromboGenics Forms Joint Venture with VIB 10
Licensing Agreements 11
Oncurious Enters into Licensing Agreement with VIB 11
ThromboGenics Enters into Licensing Agreement with Galapagos 12
ThromboGenics Enters into Licensing Agreement with Grifols 13
ThromboGenics Enters Into Licensing Agreement With Bicycle Therapeutics 14
Equity Offering 15
ThromboGenics Plans to Raise USD11.8 Million in Private Placement of Shares 15
ThromboGenics Completes Private Placement Of Shares For US$103.7 Million 16
ThromboGenics NV – Key Competitors 18
ThromboGenics NV – Key Employees 19
ThromboGenics NV – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Sep 07, 2017: ThromboGenics Business Update – H1 2017 21
Mar 16, 2017: ThromboGenics Business Update – FY 2016 25
Oct 20, 2016: ThromboGenics Business Update – Q3 2016 29
Aug 25, 2016: ThromboGenics Business Update- H1 2016 32
Corporate Communications 36
Nov 08, 2017: ThromboGenics Strengthens Leadership Team 36
Jun 15, 2017: Thomas Clay Appointed Chairman of the Board of Directors 37
Product News 38
04/20/2017: Thrombogenics Achieves Important Milestone In The Development Of THR-149, A Novel Plasma Kallikrein Inhibitor For Diabetic Macular Edema 38
Product Approvals 39
Jan 07, 2016: BioInvent announces FDA acceptance of the Investigational New Drug application for the phase I/IIa study with TB-403 39
Other Significant Developments 40
Oct 20, 2017: ThromboGenics Business Update – Q3 2017 40
May 11, 2017: ThromboGenics Business Update – Q1 2017 43
May 13, 2016: ThromboGenics Business Update – Q1 2016 46
May 13, 2016: ThromboGenics Business Update – Q1 2016 49
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
ThromboGenics NV, Pharmaceuticals & Healthcare, Key Facts, 2016 2
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ThromboGenics NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ThromboGenics NV, Deals By Therapy Area, 2011 to YTD 2017 8
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
ThromboGenics Forms Joint Venture with VIB 10
Oncurious Enters into Licensing Agreement with VIB 11
ThromboGenics Enters into Licensing Agreement with Galapagos 12
ThromboGenics Enters into Licensing Agreement with Grifols 13
ThromboGenics Enters Into Licensing Agreement With Bicycle Therapeutics 14
ThromboGenics Plans to Raise USD11.8 Million in Private Placement of Shares 15
ThromboGenics Completes Private Placement Of Shares For US$103.7 Million 16
ThromboGenics NV, Key Competitors 18
ThromboGenics NV, Key Employees 19
ThromboGenics NV, Other Locations 20
ThromboGenics NV, Subsidiaries 20

★海外企業調査レポート[ThromboGenics NV (THR)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Catalyst Paper Corp:企業の戦略的SWOT分析
    Catalyst Paper Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • BASF SE:企業の戦略・SWOT・財務情報
    BASF SE - Strategy, SWOT and Corporate Finance Report Summary BASF SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Hitachi Kokusai Electronic Inc.:企業の戦略・SWOT・財務情報
    Hitachi Kokusai Electronic Inc. - Strategy, SWOT and Corporate Finance Report Summary Hitachi Kokusai Electronic Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Toa Corp (1885):企業の財務・戦略的SWOT分析
    Toa Corp (1885) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Senzime AB (SEZI)-製薬・医療分野:企業M&A・提携分析
    Summary Senzime AB (Senzime) is a medical device company that develops patient-oriented monitoring systems. The company's product include TetraGraph monitor, CliniSenz analyzer, and Onzurf probe. Its TetraGraph monitor stimulates, measures, analyzes and displays muscle function in surgical patients …
  • Primearth EV Energy Co Ltd:企業の戦略的SWOT分析
    Primearth EV Energy Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Astron Corporation Ltd (ATR):企業の財務・戦略的SWOT分析
    Astron Corporation Ltd (ATR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • CapeRay Medical (Pty) Ltd:製品パイプライン分析
    Summary CapeRay Medical (Pty) Ltd (CapeRay), formerly African Medical Imaging is a medical device company that offers imaging solutions. The company offers breast imaging devices. It offers aceso system to detect breast cancer with standard digital mammography. CapeRay’s aceso system is used for det …
  • Innergex Renewable Energy Inc (INE):企業の財務・戦略的SWOT分析
    Innergex Renewable Energy Inc (INE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • HealthSouth Corporation:企業のM&A・事業提携・投資動向
    HealthSouth Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's HealthSouth Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Medidata Solutions Inc (MDSO)-製薬・医療分野:企業M&A・提携分析
    Summary Medidata Solutions Inc (Medidata) is a provider of cloud based solutions for life sciences sectors. It offers wide range of advanced tools for data & analytics, planning, data capture, study management, monitoring, payments, and platform services. The company offers technology and data analy …
  • GFI Informatique (GFI):企業の財務・戦略的SWOT分析
    GFI Informatique (GFI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • EDF Luminus SA:発電所・企業SWOT分析
    EDF Luminus SA - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exe …
  • Polynt SpA:企業の戦略的SWOT分析
    Polynt SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Diffusion Pharmaceuticals Inc (DFFN):企業の財務・戦略的SWOT分析
    Summary Diffusion Pharmaceuticals Inc (Diffusion), formerly Diffusion Pharmaceuticals LLC is a clinical stage biotechnology company that develops standard of care therapies. The company improves cancer treatments such as radiation therapy and chemotherapy in treatment-resistant solid tumors, includi …
  • Akari Therapeutics Plc (AKTX):企業の財務・戦略的SWOT分析
    Summary Akari Therapeutics Plc (Akari), formerly Celsus Therapeutics Plc is a biopharmaceutical company that develops treatments for rare and orphan autoimmune and inflammatory diseases. The company offers coversin drugs that act on complement component-C5 that helps in preventing the release of C5a …
  • Manitoba Hydro-Electric Board:発電所・企業SWOT分析
    Manitoba Hydro-Electric Board - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Alcami Corp:企業の戦略的SWOT分析
    Alcami Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Neurocrine Biosciences Inc (NBIX):企業の財務・戦略的SWOT分析
    Neurocrine Biosciences Inc (NBIX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Air Water Inc (4088):企業の財務・戦略的SWOT分析
    Air Water Inc (4088) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆